Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company has received the GMP Certification after successful closure of the inspection
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Subscribe To Our Newsletter & Stay Updated